- Dec 14, 2006
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this...
72
- Dec 9, 2006
FDA Approved for RRMM: Lenalidomide (Revlimid)
SUMMIT, N.J., June 29, 2006 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA)...
45
- Dec 8, 2006
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
IFM 99-06 NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma In multiple myeloma, combination...
108
- Dec 7, 2006
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
MM-015 study NCT00405756 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. The purpose...
89